BURLINGTON, Mass., Nov. 6, 2017 /PRNewswire/ -- Decision Resources Group finds that the renal anemia market will experience growth within the G7 countries during 2016 – 2026. This growth will be fueled by the emergence of new oral hypoxia inducible factor-prolyl hydroxylase (HIF-PH) inhibitors, FibroGen/Astellas/AstraZeneca's roxadustat, Akebia/Otsuka's vadadustat and GlaxoSmithKline's daprodustat. The HIF-PH inhibitors represent a novel class for treating renal anemia and, if approved, they will compete against erythropoietin stimulating agents (ESAs) and iron supplements, both of which are widely used in treating renal anemia. Renal anemia, a common complication of chronic kidney disease (CKD) captures two different populations: CKD-dialysis and chronic kidney disease nondialysis (CKD-ND).
Other key findings from the Renal Anemia: Disease Landscape and Forecast report:
- Experts interviewed anticipate significant use of HIF-PH inhibitors in the CKD-ND patient population due to their noninvasive route of administration. ESAs are administered to patients intravenously or subcutaneously, and these are not ideal options for CKD-ND patients.
- The CKD-dialysis market will not only be impacted by the launch of the HIF-PH inhibitors but also the increased availability of biosimilar ESAs. Since more CKD-dialysis patients are on ESAs than CKD-ND patients, the impact of biosimilar ESAs is expected to be larger in the CKD-dialysis population.
- The HIF-PH inhibitors are in advanced phases of development. The first HIF-PH inhibitors are expected to launch in the United States and Europe in 2018 and the Japanese market in 2019.
- Considering the cardiovascular (CV) issues associated with ESAs, interviewed experts are looking for therapies to treat renal anemia that are safer alternatives. New therapies demonstrating long-term safety and reductions in the risk of CV events would positively affect prescription of those agents.
Comments from Decision Resources Group Analyst Jihan Khan, Ph.D.:
- "Experts strongly believe that HIF-PH inhibitors address the unmet need regarding the inconvenience of ESA administration in CKD-ND patients. Should the HIF-PH inhibitors' Phase III trials generate positive outcomes, and not give rise to any major safety concerns, they will likely compete very favorably against ESAs."
- "HIF-PH inhibitors are expected to be expensive. I suspect they are going to require prior authorization, as ESAs do. However, it is not clear at this point whether the burden of that prior authorization is going to be the same for HIF-PH inhibitors versus ESAs. HIF-PH inhibitors have to price themselves right for uptake because biosimilar ESAs will also launch and these therapies are expected to be more affordable."
For more information on purchasing this report, please visit our website.
About Decision Resources Group
DRG, a subsidiary of Piramal Enterprises Ltd., is the premier source for global healthcare data and market intelligence. A trusted partner for over 20 years, DRG helps companies competing in the global healthcare industry make informed business decisions. Organizations committed to the developing and delivering life-changing therapies to patients rely on DRG's in-house team of expert healthcare analysts, data scientists, and consultants for critical guidance. DRG products and services, built on extensive data assets and delivered by experts, empower organizations to succeed in complex healthcare markets.
Decision Resources Group
SOURCE Decision Resources Group